Bone marrow involvement is a risk factor for infusion-related reactions in patients with follicular lymphoma treated by obinutuzumab

被引：1
|
作者：
Masamoto, Yosuke [1 ]
Taoka, Kazuki [1 ]
Maki, Hiroaki [1 ]
Kurokawa, Mineo [1 ,2 ]
机构：
[1] Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Tokyo, Japan
[2] Tokyo Univ Hosp, Dept Cell Therapy & Transplantat Med, Tokyo, Japan
来源：
ANNALS OF HEMATOLOGY | 2022年 / 101卷 / 12期
关键词：
Follicular lymphoma; Obinutuzumab; Infusion-related reactions; Risk factors; RITUXIMAB INFUSION; MULTICENTER;
D O I：
10.1007/s00277-022-04987-5
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页码：2795 / 2797
页数：3
相关论文
共 50 条
  • [11] Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab
    C L Freeman
    M Dixon
    R Houghton
    K-A Kreuzer
    G Fingerle-Rowson
    M Herling
    K Humphrey
    S Böttcher
    C S de Costa
    V Iglesias
    S Stilgenbauer
    J Gribben
    M Hallek
    V Goede
    Leukemia, 2016, 30 : 1763 - 1766
  • [12] CLINICAL FEATURES AND OUTCOME OF FOLLICULAR LYMPHOMA PATIENTS WITH BONE MARROW INVOLVEMENT
    Falaleeva, N.
    Tumyan, G.
    Pavlovskaya, A.
    Kovrigina, A.
    Probatova, N.
    Kondratieva, T.
    Sholohova, E.
    Tupitsin, N.
    Khakui, R.
    Poddubnaya, I.
    Osmanov, D.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 545 - 545
  • [13] Clinical features and outcome of follicular lymphoma patients with bone marrow involvement
    Falaleeva, N.
    Tumyan, G.
    Pavlovskaya, A.
    Kovrigina, A.
    Probatova, N.
    Kondratyeva, T.
    Tupitsin, N.
    Khakui, R.
    Osmanov, D.
    ANNALS OF ONCOLOGY, 2008, 19 : 210 - 211
  • [14] Management of patients with follicular lymphoma treated first line with obinutuzumab
    Opat, Stephen
    Dickinson, Michael
    Cheah, Chan Yoon
    Tam, Constantine
    Boulos, Joy
    Thorburn, Alison Nicole
    Trotman, Judith
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 3 - 11
  • [15] Predicting the risk of infusion-related reactions in ocrelizumab treatment
    Schoof, Lisa
    Hogenboom, Laura
    Mulder, Thom
    van Kempen, Zoe
    van Oosten, Bob
    Killestein, Joep
    Strijbis, Eva
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 1002 - 1002
  • [16] Clonal selection in the bone marrow involvement of follicular lymphoma
    Á Bognár
    B Csernus
    C Bödör
    L Reiniger
    Á Szepesi
    E Tóth
    L Kopper
    A Matolcsy
    Leukemia, 2005, 19 : 1656 - 1662
  • [17] Clonal selection in the bone marrow involvement of follicular lymphoma
    Bognár, A
    Csernus, B
    Bödör, C
    Szepesi, A
    Tóth, E
    Kopper, L
    Matolcsy, A
    ANNALS OF ONCOLOGY, 2005, 16 : 149 - 149
  • [18] Clonal selection in the bone marrow involvement of follicular lymphoma
    Bognár, A
    Csernus, B
    Bödör, C
    Reiniger, L
    Szepesi, A
    Tóth, E
    Kopper, L
    Matolcsy, A
    LEUKEMIA, 2005, 19 (09) : 1656 - 1662
  • [19] Clonal selection in the bone marrow involvement of follicular lymphoma
    Bognár, A
    Csernus, B
    Bödör, C
    Szepesi, A
    Matolcsy, A
    TISSUE ANTIGENS, 2004, 64 (04): : 390 - 390
  • [20] The Value of PET/CT in Detecting Bone Marrow Involvement in Patients With Follicular Lymphoma
    Perry, Chava
    Lerman, Hedva
    Joffe, Erel
    Sarid, Nadav
    Amit, Odelia
    Avivi, Irit
    Kesler, Mikhail
    Ben-Ezra, Jonathan
    Even-Sapir, Einat
    Herishanu, Yair
    MEDICINE, 2016, 95 (09)
12345